274 related articles for article (PubMed ID: 26675887)
1. The dopamine D1 receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets.
Kotani M; Kiyoshi A; Murai T; Nakako T; Matsumoto K; Matsumoto A; Ikejiri M; Ogi Y; Ikeda K
Behav Brain Res; 2016 Mar; 300():25-30. PubMed ID: 26675887
[TBL] [Abstract][Full Text] [Related]
2. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic modulation of risk-based decision making.
St Onge JR; Floresco SB
Neuropsychopharmacology; 2009 Feb; 34(3):681-97. PubMed ID: 18668030
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats.
Desai RI; Neumeyer JL; Bergman J; Paronis CA
Behav Pharmacol; 2007 Dec; 18(8):745-54. PubMed ID: 17989512
[TBL] [Abstract][Full Text] [Related]
5. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
6. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
[TBL] [Abstract][Full Text] [Related]
7. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
8. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
Graham DL; Hoppenot R; Hendryx A; Self DW
Psychopharmacology (Berl); 2007 Apr; 191(3):719-30. PubMed ID: 16835769
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.
Scardochio T; Clarke PB
Psychopharmacology (Berl); 2013 Apr; 226(3):589-600. PubMed ID: 23192317
[TBL] [Abstract][Full Text] [Related]
10. Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets.
Nakako T; Murai T; Ikejiri M; Ishiyama T; Taiji M; Ikeda K
Behav Brain Res; 2013 Jul; 249():109-15. PubMed ID: 23608483
[TBL] [Abstract][Full Text] [Related]
11. Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.
Desai RI; Neumeyer JL; Paronis CA; Nguyen P; Bergman J
Eur J Pharmacol; 2007 Mar; 558(1-3):98-106. PubMed ID: 17207791
[TBL] [Abstract][Full Text] [Related]
12. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
13. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey.
Elsworth JD; Lawrence MS; Roth RH; Taylor JR; Mailman RB; Nichols DE; Lewis MH; Redmond DE
J Pharmacol Exp Ther; 1991 Nov; 259(2):595-600. PubMed ID: 1682479
[TBL] [Abstract][Full Text] [Related]
14. D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat.
Cruz-Trujillo R; Avalos-Fuentes A; Rangel-Barajas C; Paz-Bermúdez F; Sierra A; Escartín-Perez E; Aceves J; Erlij D; Florán B
Neuropharmacology; 2013 Apr; 67():370-8. PubMed ID: 23238327
[TBL] [Abstract][Full Text] [Related]
15. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
Braun AR; Laruelle M; Mouradian MM
J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
Rossi NF
Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H; Gerlach J; Mørkeberg F
Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
[TBL] [Abstract][Full Text] [Related]
18. Intravitreally-administered dopamine D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews.
Ward AH; Siegwart JT; Frost MR; Norton TT
Vis Neurosci; 2017 Jan; 34():E003. PubMed ID: 28304244
[TBL] [Abstract][Full Text] [Related]
19. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats.
Barrett AC; Miller JR; Dohrmann JM; Caine SB
Neuropharmacology; 2004; 47 Suppl 1():256-73. PubMed ID: 15464142
[TBL] [Abstract][Full Text] [Related]
20. Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors.
Chaperon F; Tricklebank MD; Unger L; Neijt HC
Neuropharmacology; 2003 Jun; 44(8):1047-53. PubMed ID: 12763098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
